US Pharma MarketingBiotech's bull market, Vertex's gene therapy expansion, and more news from The Readout Obesity research Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout Roche drug sets new standard for KRAS-driven lung cancer Biotech’s bull market, Vertex’s gene therapy expansion, and more news from The…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hi! As ever, lots going on in the light-speed world of biotech. The sector’s rally is gathering steam, the FDA’s AI flexibility is getting lost in translation, and Democrats lose a seasoned biopharma policymaker.
But I’m still reeling from that synthetic biology SpudCell Matt Herper wrote about.
Source: STAT News Pharma